Tolcapone
Other Dopaminergic Agents
Sold as Tasmar
- Drug class
- Other Dopaminergic Agents
- Availability
- See label
- Markets covered
- 2
- Products on record
- 3
Overview
Tolcapone is an active pharmaceutical ingredient in the Other Dopaminergic Agents group (N04BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | April 17, 2026 |
| EU European Union | EMA | 1 | September 10, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
1). 8). Since Tasmar should be used only in combination with levodopa/benserazide and levodopa/carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.
How to take
EUEuropean Union· EMA
1 product
Uses
1). 8). Since Tasmar should be used only in combination with levodopa/benserazide and levodopa/carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.
How to take
Drug interactions
Known interactions involving Tolcapone. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 251. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB463020207 · revised April 17, 2026
- [2]European Medicines Agency · EMEA/H/C/000132 · revised September 10, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.